Revisiting the use of albumin in patients with cirrhosis – trial design matters

Abstract

Section snippets

Authors' contributions

All authors contributed equally to the production of this manuscript.

Financial support

None.

Declaration of Competing Interest

PG has received research funding from Gilead and Grifols. PG has consulted or attended advisory boards for Gilead, RallyBio, SeaBeLife, Merck, Sharp and Dohme (MSD), Ocelot Bio, Behring, Roche Diagnostics International, Boehringer Ingelheim and Astra-Zeneca, and received speaking fees from Pfizer. The other authors have declared no conflict of interest.Please refer to the accompanying ICMJE disclosure forms for further details.

Acknowledgements

None.